Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Valerio Zoli et al.|Journal of Clinical Oncology|2010Cited by 167
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi et al.|Neurology|2022Cited by 38
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Corrado Tarella, Fabio Benedetti et al.|Haematologica|2019Cited by 19
Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL TrialCorrado Tarella, Marco Ladetto, Fabio Benedetti et al.|Blood|2013Cited by 4
Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients.Corrado Tarella, Alessandro Rambaldi, Manuela Zanni et al.|Blood|2006Cited by 4